YUNMAI
21.7.2022 11:53:08 CEST | Business Wire | Press release
The leading wellness equipment brand Yunmai is announcing the #YunmaiAthletes community campaign. Yunmai serves professional players across different sports by supporting them with professional, effective, and portable muscle recovery solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220718005331/en/
In April 2021, Yunmai announced its first Global Brand Ambassador, Ansu Fati, the "New No. 10" from FC Barcelona, who inherited the number from Lionel Messi, for its line of massage guns. “Join Yunmai Athletes, enter a new dimension, and achieve your peak athletic performance,” said Ansu Fati. At the young age of 17 years, Fati had already set athletic world records that made him the obvious choice to represent Yunmai on a global stage.
Yunmai‘s products are designed to empower sports enthusiasts and especially professional athletes to fully control their fitness and wellness. For many athletes, Yunmai massage guns have been part of their daily training routine to enhance their performance during competitions. In addition to Ansu Fati, the world’s No. 1 Badminton player Viktor Axelsen, who has won two Olympic medals, favors his Yunmai Massage Gun Pro Basic: “To keep my training session challenging, it's essential to have Yunmai relaxation gadgets at my disposal.”
Three-time Olympic gold medalist Kaillie Humphries also approves of the powerful Yunmai Massage Gun Slim Chic: “Whether I'm warming up before lifting or cooling down after a competition, the Yunmai massage gun helps me recover faster.” Humphries’ hard training and winning moments on the field are enabled by Yunmai’s high-quality percussive therapy devices to improve her pre-workout activation and post-workout muscle recovery.
Yunmai is dedicated to help users “Simplify Your Workout” and unlock the best version of themselves with quick warm-ups, instant recovery, and precise data tracking. “I love how Yunmai lets me take control of recovery in a simple and efficient way,” explained Joey Haywood, the streetball legend from Canada.
Yunmai specializes in technology-driven massage guns, smart scales, and smart jump ropes, which are sold in over 115 countries today. Yunmai’s award-winning products have been featured in a wide range of well-known global media outlets, including CNN, Forbes, Rolling Stone, and the Wall Street Journal.
About Yunmai
The sports and fitness brand Yunmai has been using technology and innovation to enhance workouts since 2014. Yunmai pioneered the manufacturing of smart scales and continues to innovate in the smart health market.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220718005331/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom